Researchers in Germany have demonstrated a novel approach to detecting disease by analyzing volatile organic compounds (VOCs) emitted from specific body sites, including the nostrils, belly button, and ear concha. The pilot study, conducted by the Fraunhofer Institute for Integrated Circuits, suggests that sampling these chemical signatures, collectively referred to as the human volatilome, may provide a non-invasive method for early illness screening.
The human body naturally releases VOCs through processes such as exhalation, sweating, and shedding skin cells. Variations in these chemical profiles have been linked to certain health conditions, as evidenced by anecdotal reports of animals detecting diseases like cancer before clinical diagnosis. Building on this premise, the research team sought to identify distinct VOC patterns associated with Parkinson’s disease, Covid-19, and mild cognitive impairment.
The study included 24 participants, divided into healthy controls and individuals diagnosed with one of the three targeted conditions. Swabs were taken from three sites—nostrils, belly button, and the outer ear—each for approximately ten seconds. Following collection, the samples were frozen at –20 degrees Celsius to preserve the compounds. Analysis employed laser-based photoacoustic spectroscopy, which characterizes the chemical makeup of VOCs by detecting their vibrational response to light at various wavelengths.
Results indicated that VOC patterns allowed differentiation between healthy and diseased participants, with the most reliable signals obtained from the nostrils and belly button samples. Furthermore, the researchers found that only a limited range of wavelengths was necessary to capture the critical information, potentially allowing for simplified, faster diagnostic devices in the future.
Lead researcher Dr. Thorsten Graunke highlighted the potential for such swabbing to be performed by individuals themselves, noting the possibility of developing handheld devices capable of rapid screening at home. However, he emphasized that these ambitions remain long-term goals, pending further validation in larger studies. The current trial was conducted under controlled conditions for most participants; Covid-19 patients collected their own samples due to infection control protocols.
The study aligns with a growing interest in non-invasive diagnostics based on body odor analysis. Professor James Logan, an olfactory science specialist and founder of a company developing VOC detection tools for diseases such as dengue and malaria, praised the research as advancing understanding in the field. He noted that odor-based detection offers advantages over traditional tests by being non-invasive and capable of identifying infections at earlier stages.
Professor Logan also underscored the importance of selecting appropriate sampling sites. While prior research often examined the armpits, the presence of deodorants complicates VOC analysis. The belly button, less frequently cleaned or treated with external products, may provide a more reliable source of disease-associated VOCs.
Applications of odor detection in medicine are already emerging, including trained dogs that can identify Covid-19 and impending medical events such as seizures or blood sugar fluctuations. Experts foresee that technological advancements could soon enable compact devices—potentially integrated into wearable technology—to detect health changes through VOCs with increasing precision.
Though preliminary, the new study contributes to the expanding evidence that disease-specific VOC signatures exist and can be harnessed for diagnostic purposes, potentially transforming how illnesses are screened and monitored in clinical and home settings.